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INTRODUCTION
Follistatin is a regulatory glycoprotein with a myriad of biological functions in humans. (Ueno, Ling et al. 1987; Kogure, Omata et al. 1995; Kogure, Zhang et al. 1996; Fuwii, Ishikawa et al. 2005; Fumagalli, Musso et al. 2007; Kota, Handy et al. 2009 ) It is involved in the regulation of early fetal development and cellular differentiation, regulating follicle stimulating hormone (FSH) and luteinizing hormone (LH) release and action (Carroll, Kowash et al. 1991; Barakat, O'Connor et al. 2008; Aroua, Maugars et al. 2012) , wound healing (Fumagalli, Musso et al. 2007) , tissue regeneration and repair, including bone, muscle and skin (Inoue, Orimo et al. 1994; Funaba, Ogawa et al. 1996; Gajos-Michniewicz, Piastowska et al. 2010; Gajos-Michniewicz, Pawlowska et al. 2012) , and limiting cancer cellular proliferation. (Ogino, Yano et al. 2008; Tumminello, Badalamenti et al. 2010; Karve, Preet et al. 2012; Ren, Chen et al. 2012; Sepporta, Tumminello et al. 2013) In all cases, these regulatory functions are conferred via its direct engagement with and potent antagonism (and in some cases agonism) of members of the TGFβ-like family of proteins. The diverse biological regulatory properties embodied by follistatin have spurred considerable interest to develop follistatin-based therapeutics to treat a wide array of potential indications. Indeed several groups have reported potent beneficial effects of follistatin administration in various indications such as, inflammation, liver repair, fibrosis, wound healing, hair regrowth and muscle disorders, including muscular dystrophy. (Kogure, Omata et al. 1995; Wankell, Munz et al. 2001; Fuwii, Ishikawa et al. 2005; Fumagalli, Musso et al. 2007; Tsuchida 2008; Zimber, Ziering et al. 2011; Datta-Mannan, Yaden et al. 2012; de Kretser, O'Hehir et al. 2012) Although, many studies indicate follistatin has the potential D M D # 6 4 5 1 9
5 to be applied to various diseases, the development of follistatin as a biotherapeutic remains a relatively unexplored frontier. This is likely due to its high degree of molecular complexity, structural properties and post-translational glycosylation which create significant challenges in optimizing the molecule's structure-activity relationship along with its in vivo pharmacokinetic/pharmacodynamic (PK/PD) properties. Human follistatin is a structurally complex molecule that is comprised of 344 residues that is present in two major isoforms which result from alternative mRNA splicing: follistatin-315 (FST315) and follistatin-288 (FST288) (For a review see ref (Phillips and De Kretser 1998) ). Both isoforms contain identical core regions that are formed from a series of tandemly repeated domain elements: An N-terminal domain (FST 0), followed by three successive KAZAL/EGF-like repeats units (deemed FST 1, 2 and 3) and a highly acidic C-terminal tail (Keutmann, Schneyer et al. 2004 ) (Figure 1 ). The primary sequence of follistatin is punctuated by a preponderance of 36 cysteine residues which form 18 disulfide bonds that interlink the aforementioned domain elements and that stabilize the overall protein structure. Together these various elements provide a structural scaffold which allows follistatin to interact with TGFβ-like ligands. (Thompson, Lerch et al. 2005; Cash, Rejon et al. 2009 In our previous studies, we reported the first published example of the successful engineering of a FST315 variant, deemed FST-ΔHBS-Fc, which has the potential to serve as a platform for developing a parenterally administered biotherapeutic (DattaMannan, Yaden et al. 2012) in the treatment of diseases where muscle atrophy is implicated (Yaden, Croy et al. 2014) . In these studies we fused follistatin 315 to an IgGderived Fc and removed the protein's intrinsic heparin binding activity to generate FST-ΔHBS-Fc. Following protein engineering, FST-ΔHBS-Fc exhibited ~1600-fold and ~90-fold improvements in exposure and half-life, respectively, in mice relative to unmodified FST315 (Datta-Mannan, Yaden et al. 2012 ). This molecule, in contrast to FST315, also displayed robust, dose-dependent pharmacological effects when administered subcutaneously on a weekly basis in a mouse model of muscle atrophy (Datta-Mannan, Yaden et al. 2012) .
One aspect of follistatin not covered in our previous studies was the impact of Nlinked glycosylation on the pharmacokinetic behavior of various FST-ΔHBS-Fc molecules. Heterogeneity in glycosylation is an important consideration when optimizing a glycoprotein for systemic therapeutic use. The main outcome of suboptimal sialylation of solvent exposed N-linked glycans in Epo or other glycoproteins (Mortensen and Huseby 1997; Bork, Horstkorte et al. 2009; Richards, Colgrave et al. 2010 ) leads to recognition and subsequent removal of the compound from circulation via a sugar-based interaction with a specialized subset of lectin-type receptors present on hepatic cells, called the asialoglycoprotein receptors (ASPGRs) (reviewed in (Ashwell and Harford 1982) ). Given the close association of the exposure-response relationship we observed for FST-ΔHBS-Fc in our previous studies, optimization of the
pharmacokinetic properties (and by extension pharmacodynamics) of a follistatin-based therapeutic must ensure that optimal glycan character is well characterized and defined.
Herein we present the influence of N-linked glycosylation on the pharmacokinetics of two FST-ΔHBS-Fc constructs (deemed MV9 and MV12). First, we found there was a strong correlation between the degree of sialylation with the clearance of the engineered FST-ΔHBS-Fc variants in both mice and Cynomolgus monkeys.
Additionally, the examination of the pharmacokinetics of a subset of the FST-ΔHBS-Fc molecules in ASPGR-1 knockout mice further implicated the role of lectin-type receptors in the clearance of these molecules. Significantly, these studies highlight the molecular complexity inherent in the production of recombinant follistatin from mammalian cell culture and the dependence of in vivo pharmacokinetic properties on the extent and composition of the carbohydrates present on the molecule.
MATERIALS AND METHODS

Expression and purification of recombinant MV9 and MV12 FST-ΔHBS-Fc proteins
The MV9 and MV12 variants described within this report were expressed in stablytransfected Chinese hamster ovary cells and were generated at Eli Lilly (Indianapolis, IN, USA). The primary amino acid sequences for MV9 and MV12 are provided in the supplemental data section of this manuscript (supplemental protein sequences).
Isolation of proteins from concentrated cell culture supernatants involved capture by Mab select Sepharose (GE Healthcare) affinity chromatography, followed (in certain instances) by hydrophobic interaction chromatography, and finally by preparative gel filtration chromatography. These steps generally resulted in protein purity in excess of 98%, as assessed by analytical gel filtration on a TSKG3000SWXL column.
LCMS characterization of glycosylation profiles for MV9 and MV12
LC/MS characterization of glycosylation profiles of MV9 and MV12 was conducted for immune affinity captured materials. When murine plasma samples contained at least 400 ng of either MV9 or MV12 the sample was mixed with 15 μl of magnet beads suspension immobilized anti-human IgG4 Fc antibody (4 mg antibody/10 ml the suspension) and then incubated at ambient temperature for approximately 100 min.
Sample beads were then washed with 3×100 μl of 1xPBS (phosphate buffered saline) material was released by incubating with 20 μl and then 10 μl of 20 mM sodium citrate buffer, pH 3.0. Each released solution was mixed with 4 μl of 1 M tris-HCl buffer, pH 8, 0.5 ml of 50 mg/ml DTT solution and then treated with 1 μl of 0.2 mg/ml Lys-C solution at 37⁰C for two hours. Each digest was alkylated with 1 μl of 100 mg/ml iodoacetamide reversed phase column (1.0x100 mm, 1.7 μm particle size) using 0.15% formic acid 
Murine pharmacokinetic studies
Several murine pharmacokinetic studies were conducted at a contract research knockout mouse study. In each study, the mouse blood samples were collected by saphenous vein, tail clip, retro-orbital or cardiac puncture into tubes containing sodium EDTA as anticoagulant and processed to plasma.
Cynomolgus monkey pharmacokinetic studies
The Cynomolgus monkey pharmacokinetic study was conducted at a contract research organization (Covance Laboratories, Madison, WI). The conduct of the nonhuman primate study was within the established requirements of the humane animal use standards and guidelines established by Covance. Twelve male Cynomolgus monkeys (2-to 5-kg) were assigned to one of four study groups. Each animal received a single intravenous (IV) dose of FST-ΔHBS-Fc characterized with 16%, 27%, 33% or 60% overall starting sialic acid content dissolved in PBS, pH 7.4, at 1 mg/kg. Blood samples were collected from the femoral vein at 0.083, 1, 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 288, 336, 384, 456, 528 , 600 and 672 hours after
administration of the dose. Blood samples were allowed to clot at ambient temperature prior to centrifugation to obtain serum.
Bioanalytical assays for the pharmacokinetic samples and pharmacokinetic data analysis
Concentrations of the FST-ΔHBS-Fc variants with different overall starting sialic acid content in mouse plasma or Cynomolgus monkey serum were determined using mini- ng/mL in Cynomolgus monkey serum, respectively, for each of the sialic acid variants; whereas, the LLOQ and ULOQ in mouse plasma were 1.4 and 75 ng/mL, respectively, for all the constructs. Storage stability at -70 °C in neat matrix was established for up to 30 days for each of the variants.
Pharmacokinetic parameters were calculated using the WinNonlin Professional 
RESULTS
In vitro binding properties and pharmacokinetics of the MV9 and MV12 in SCID mice
In our previously published work, we showed that fusion of FST315 to a Fc fragment of IgG and removal of its intrinsic heparin sulfate binding activity resulted in a PK/PD profile that supported parenteral delivery. Table 1 , respectively).
In addition, we also performed a pharmacokinetic assessment of these two molecules in SCID mice. The average concentration-time profiles for MV9 or MV12 following a single 10 mg/kg subcutaneous administration are shown in Figure 2 . Both molecules displayed a rapid distribution phase followed by a longer elimination phase characteristic of Fc fusion proteins. When compared to each other, MV12 exhibited an approximate 2-fold higher exposure (AUC) than MV9 (Table 1) .
Liquid chromatography mass spectrometry (LCMS) based characterization of glycosylation properties in MV9 and MV12
Given the large degree of carbohydrate predicted to be present in MV9 and MV12, we hypothesized that the pharmacokinetic differences observed in between the variants (Figure 2 ) may in part be driven by differences in their overall glycosylation attributes.
To better understand how glycan heterogeneity influenced the pharmacokinetic properties of MV9 and MV12, we performed an extensive LCMS-based characterization of the N-linked glycosylation profiles of the starting materials used in the aforementioned murine pharmacokinetic study. In the first experiment, we examined the sugar occupancies in MV9 and MV12 at each of the predicted sites based on primary acid amino acid sequence of the variants (Figure 1 ). The MS analyses indicated that each of the predicted FST N-linked sites (N95, N112, N295), as well as, the Fc site (N398) in both MV9 and MV12 contained varying carbohydrate occupancies (Supplemental Figure 2) . Although varied in occupancy each N-linked site in MV9 and MV12 was observed to exhibit a unique preference for a specific carbohydrate antennary structure that was conserved across variants (Supplemental Figure 3A) .
Taken together these results suggest that the gross carbohydrate antennary structural preferences of the FST-ΔHBS-Fc variants are likely governed in a site-specific manner;
perhaps by primary amino acid sequence and/or tertiary structures surrounding the Nlinked attachment sites.
We next used MS to examine the detailed character of the carbohydrate termini oligosaccharide present in the starting materials used in the aforementioned mouse pharmacokinetic study. Examination of the N-linked glycans present in the FST region of both proteins showed that the degree of sialylation was greater in MV12, relative to MV9, resulting in an overall average of 46% more sialic acid per oligosaccharide in MV12 (Figure 3) . It was also noted that in both variants the degree of sialylation at N398 was comparable and low (data not shown). Closer analysis of the asialylated species in both MV9 and MV12 showed that carbohydrate termini preferentially terminated in galactose, (Supplemental Figure  4A ) followed by Nacetylglucosamine/mannose (Supplemental Figure 4B ). Given the differences observed in these two proteins, we wanted to understand the impact of lot to lot variation on the glycosylation properties of FST-Fc and therefore characterized by LCMS the overall average sialylation percentage of 12 independently produced lots of MV9 and MV12 using a fixed cell culture and purification process. Unlike the conservation noted in the average antennary structures (Supplemental Figure 3A ) of these molecules, the degree of site-specific sialylation (Supplemental Figure 3B ) was observed to be highly varied in our expression system. These data suggest that the differential sialylation properties of MV9 and MV12 were most likely the result of lot to lot variability in their overall glycosylation properties and not the result of the differences in their overall chemical structures.
Correlation of pharmacokinetic properties of MV9 and MV12 with specific changes in glycosylation attributes
Given the pharmacokinetic differences highlighted in Figure 2 and and MV12 materials recovered at 0 and 336 hours are described in Figure 4 . The results show significant changes in the relative ratios of each specific terminus evaluated for both MV9 and MV12. Kinetically, these changes were punctuated by a rapid-compositional change which occurred prior to first time point measured in our study (T=12hrs), after which a slower rate of change was observed (Supplemental site ( Figure 4A and 4B). Overall, a comparative analysis of the degree of change in starting vs. terminal circulating sialylated species was ~50% greater in MV9, relative to MV12, which likely reflects the preferential clearance of poorly sialylated species during prolonged circulation. One final observation was that though carbohydrates present at the Fc-position N398 were found to be largely asialylated (Supplemental Figure 2) , these species were not altered to an appreciable amount during extended circulation in vivo (data not shown). This finding is consistent with other published studies on antibody-therapeutic fusions. (Jefferis 2005) .
Pharmacokinetics of MV9 and MV12 sialic acid variants in SCID mice and Cynomolgus monkeys
Given the connection between the starting material's sialic acid content and the effect on its pharmacokinetic profile, we further characterized the impact of variable sialic acid content in the FST-ΔHBS-Fc variants by expressing and purifying several independent lots of MV9 and MV12, each containing differential overall average sialic acid content (quantified by LCMS analysis; Table 2 ). The pharmacokinetics of the MV9 molecules with varying average sialic acid content were evaluated in both SCID mice and Cynomolgus monkeys; the MV12 proteins were only examined in SCID mice. The results of these studies showed a biphasic clearance profile characterized by a rapid distribution phase followed by a longer elimination phase; consistent with the mouse studies presented above (Figure 2 mice and Cynomolgus monkeys. The MV9 and MV12 sialic acid variants showed mean clearance values ranging from 0.64 to 2.01 mL/h/kg in SCID mice (Table 2) ; whereas, in Cynomolgus monkeys, the MV9 sialic acid variants had mean clearance values ranging from 0.95 to 7.47 mL/h/kg (Table 3) . Additionally, no anti-drug antibodies were detected following administration of any of the variants to Cynomolgus monkey (data not shown);
anti-drug antibodies were not measured in the mouse studies given the compromised immune system background of SCID mice.
The sialic acid variants display a pattern of slowed mean clearance (CL) with increasing sialic acid content in both species (Figures 5 and 6 ; Tables 2 and 3 ).
Pairwise statistical analyses of the monkey data showed statistically significant clearance differences (p value <0.05) between the following pairs: 16% and 60%
variants; 16% and 33% variants; and 16% and 27% variants. Though statistically significant differences in clearance were not observed for any other pairs in monkey, the data suggests a trend for further decreasing clearance with increased average sialic acid content up to 60% (highest tested). Similar trends were observed in the murine data, but due to the nature of the sparse sampling design, no statistical analyses of the murine pharmacokinetic data were performed.
The influence of the overall average sialic acid content differences of the MV9 and MV12 variant's elimination half-life values in SCID mice and Cynomolgus monkeys was more marginal that the effects on clearance (Tables 2 and 3 ). In SCID mice and Cynomolgus monkeys, the half-lives of the variants ranged from ~200 to ~300 hours and ~100 to ~200 hours, respectfully. Pairwise statistical analyses showed no statistically significant differences in half-life between the variants in monkeys. Analysis 
Pharmacokinetics of the MV9 sialic acid variants in ASPGR-1 Knockout Mice
To determine whether the clearance mechanism of the FST-ΔHBS-Fc molecules was due to interaction with a specialized subset of lectin-type receptors present on hepatic analyses of materials collected from a head-to-head pharmacokinetic study in SCID mice ( Figure 2 ). In these studies we found, MV12 exhibited an approximate 2-fold slower clearance relative to that of MV9 (Table 1) . More striking was the fact that both molecules showed a lower than anticipated exposure (AUC) for an Fc fusion protein (Czajkowsky, Hu et al. 2012) . Possible mechanisms that could account for the clearance profile differences between the therapeutic-Fcs include: (1) heparin binding, (2) target mediated clearance, (3) FcRn interactions and/or (4) anti-drug immune response. Given that both MV9 and MV12 displayed no heparin binding in vitro (Supplemental Figure 1) and that the predicted targets for follistatin (ie. TGFβ-like family members) have low circulating levels in mice ( (Wu, Chen et al. 2012 ) and unpublished data) it was unlikely that either heparin binding in vivo or binding to target were clearance mechanisms which could explain the pharmacokinetic differences observed.
Moreover, formation of anti-drug antibodies was also unlikely to account for the observed clearance differences as these pharmacokinetic studies were performed in sialylated proteins corroborated our hypothesis on the role of terminal glycosylation in affecting the pharmacokinetics of these molecules (Figures 5 and 6 ). In mice, both MV9
and MV12 variants containing increased initial sialic acid content were cleared more slowly from mice than variant molecules containing lower sialic acid content ( Figure 5 and Table 2 ). We also found MV9 and MV12 sialic acid variants displayed similar kinetics in vivo when the sialic acid content was similar. These data indicate the residue differences across MV9 and MV12 within the HBS to reduce heparin binding impacted pharmacokinetics similarly. Thus, in pharmacokinetic experiments reported herein, the exposure differences between the molecules were predominantly driven by dissimilarities in glycosylation (sialylation) and not primary amino acid differences. It is worth noting, that the examination of the pharmacokinetics of a subset of MV9 sialic acid variants in Cynomolgus monkeys showed findings similar to that in mice with clearance values increasing for constructs with lower initial sialic acid content ( Figure 6 and Table 3 ). Additionally, within both species, the elimination half-life was similar across the sialic acid variants (Tables 2 and 3 ). These findings can be explained by the enrichment of optimally sialylated constructs in each population over time; thus, it is important to understand that although characterization of the average overall sialic acid content of the starting material is a useful and pragmatic approach to estimate clearance properties, each lot of protein is still heterogeneous and contains molecules with variable sialylation.
The negative impact of suboptimal sialylation on the pharmacokinetic behavior of
FST-ΔHBS-Fc molecules is a theme that has been explored in other glycotherapeutics
and is an important consideration for future development of systemically acting
follistatin-based therapies. Specifically, several studies exploring the clearance attributes (Webster, Phipps et al. 2003; Webster, Edgington et al. 2006 ) of UK-279,276, a glycosylated recombinant neutrophil inhibitor factor, has strongly implicated a potential clearance mechanism that involves the binding and subsequent removal of poorly sialylated species via an avidity-driven interaction with specialized hepatic lectins, called the asialoglycoprotein receptors (ASPGR). (Weiss and Ashwell 1989; Spiess 1990; Stockert 1995) Based on the similarities in our findings with those reported for UK-279,276, we performed a limited pharmacokinetic assessment of two MV9 sialic variants containing either a low (~16%) or high (~60%) average sialic acid content in ASPGR-1 knockout mice to provide a mechanistic explanation of our findings ( Figure 8 and Table 4 ). Indeed, in SCID mice and Cynomolgus monkeys the ~60% sialic acid variant exhibited an ~3.1-fold and ~7.5-fold slower clearance relative to the ~16% sialic acid variant, respectively; this difference in clearance was reduced to ~1.6-fold in the ASPGR-1 knockout mice. The reduced clearance difference between the variants in the knockout mice relative to SCID mice supports the notion of ASPGR as a route of clearance for FST-ΔHBS-Fc. However, it is important to note that because we used a higher dose in our pharmacokinetic evaluations of the variants in knockout mice (10 mg/kg) relative to the SCID mice (1 mg/kg), that this may have influenced our exposure findings. Therefore, a deeper understanding of exposure linearity across dose levels within the mice is needed to more fully interrogate the role of ASPGR-1 in the clearance of our molecules. It is also possible that other underdetermined attributes (i.e. charge distribution, aggregation potential, hydrophobicity and solubility differences) may influence the pharmacokinetic behavior of these molecules as has been reported
recently for other biologics. Interestingly, we also noted for reasons unknown to us, the effect of the variable sialylation on the clearance was more pronounced in monkeys than in mice for the MV9 constructs (compare Figure 5 with Figure 6 and compare Table 2 with Table 3 ). The findings were not related to anti-drug antibodies affecting the clearance of the molecules in Cynomolgus monkeys (data not shown). However, the observations may be due to the ASPGR mechanism playing a greater role in the higher species relative to the rodent. It's also possible that the physiochemical properties of the molecules lead to some differences in non-specific or unintended binding across the species, which was not assessed within the context of our current efforts. Further studies are required to determine these underlying aspects of the species differences in FST-ΔHBS-Fc pharmacokinetic behavior.
In summary, our previous (Datta-Mannan, Yaden et al. 2012 ) and current studies highlight the exquisite importance of understanding the interplay between heparin binding and glycosylation on the overall PK properties of follistatin-based therapies.
The current studies in this report indicate that the residue differences between MV9 and MV12 within the HBS to reduce heparin binding impacted pharmacokinetics similarly and the observed PK differences between the two molecular platforms was predominantly driven by differences in glycosylation (sialylation) and not primary amino acid differences. Furthermore, these studies serve to illustrate the extreme degree of molecular complexity inherent in the production of recombinant follistatin from 
